Group 1 - The core point of the article is that Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, leading to the termination of its major asset restructuring plan [2] - Nanjing Pharmaceutical signed an acquisition intention agreement with Future Pharmaceutical on August 26, 2025, which was expected to constitute a major asset restructuring according to relevant regulations [2] - The company has faced continuous revenue decline since its listing in 2020, with a significant loss of 357 million yuan in 2024 and a 71.28% year-on-year revenue drop in the first half of 2025 [3] Group 2 - As of September 30, Nanjing Pharmaceutical's stock price closed at 11.37 yuan per share, with a market capitalization of 3.12 billion yuan [7] - In the first half of 2025, the company reported revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan, with a non-recurring net profit loss of 41.7314 million yuan [3]

格隆汇9月30日丨南新制药(688189.SH)公布，公司近日收到中国证券监督管理委员会(以下简称"中国证 监会")出具的《立案告知书》。因公司涉嫌年报信息披露违法违规，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

Core Points - Nanjing Pharmaceutical (688189) announced the termination of its major asset restructuring plan [2] - The company had previously signed a letter of intent to acquire assets from Future Pharmaceutical, which includes three entities [2] - Despite multiple discussions and negotiations regarding the feasibility and core terms of the transaction, the parties could not reach an agreement [2] - To protect the interests of the company and its shareholders, all parties agreed to terminate the transaction and signed a termination agreement [2]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

南新制药(688189.SH)发布公告，此前，公司与西藏未来生物医药股份有限公司、许昌未来制药有限责 任公司和合肥市未来药物开发有限公司(以下合称"未来医药"或"标的公司")签署了《收购意向协议》， 公司拟以现金方式收购未来医药持有的标的资产组。 《收购意向协议》签署后，公司积极组织交易各方推进本次交易。公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见。 为切实维护公司及全体股东利益，经公司审慎研究，并与交易对方友好协商，交易各方一致同意终止筹 划本次交易，并于近日签署了《收购终止协议》。 ...

南新制药(688189.SH)发布公告，公司近日收到中国证券监督管理委员会(简称"中国证监会")出具的《立 案告知书》(编号：证监立案字0132025024号)。因公司涉嫌年报信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 ...

《收购意向协议》签署后，公司积极组织交易各方推进本次交易。公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见。 为切实维护公司及全体股东利益，经公司审慎研究，并与交易对方友好协商，交易各方一致同意终止筹 划本次交易，并于近日签署了《收购终止协议》。 南新制药(688189.SH)发布公告，此前，公司与西藏未来生物医药股份有限公司、许昌未来制药有限责 任公司和合肥市未来药物开发有限公司(以下合称"未来医药"或"标的公司")签署了《收购意向协议》， 公司拟以现金方式收购未来医药持有的标的资产组。 ...

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation into alleged violations of annual report information disclosure laws [1] Group 1 - The CSRC has issued a "Notice of Case Filing" (No. 0132025024) against the company [1] - The investigation is based on suspicions of illegal information disclosure in the company's annual report [1] - The case is being pursued under the Securities Law of the People's Republic of China and the Administrative Penalty Law [1]

北京商报讯（记者 丁宁）9月30日晚间，南新制药(688189)公告称，公司近日收到中国证监会出具的 《立案告知书》，因公司涉嫌年报信息披露违法违规，中国证监会决定对公司立案。 南新制药表示，立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法律法规及监 管要求及时履行信息披露义务。 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-043 湖南南新制药股份有限公司 关于收到中国证券监督管理委员会《立案告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）近日收到中国证券监督管 理委员会(以下简称"中国证监会")出具的《立案告知书》（编号：证监立案字 0132025024 号）。因公司涉嫌年报信息披露违法违规，根据《中华人民共和国证 券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法 律法规及监管要求及时履行信息披露义务。 公司指定信息披露媒体为上海证券交易所网站（www.sse.com.cn）和《上海 证券报》《中国证券报》《证券日报》《证券时报》，公司相关信息均以在上述指定 媒体刊登的公告为准。敬请广大投资者理性投资，注意投资风险。 特此公告。 湖南南新制药股份有限公司董事会 2025 年 10 月 1 日 ...